Study Phase 2

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis

Trial Information

Generic NameUstekinumabProduct NameSTELARA®Therapeutic AreaSkin and Connective Tissue DiseasesEnrollment320% Female30.6%% WhiteN/A
Product ClassAntipsoriaticsSponsor Protocol NumberC0379T04Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)45

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.